| Name
|
Enfuvirtide (T-20)
|
| Other Name
|
ENF
|
| Sequence (Single letter abbreviations)
|
Ac-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF-NH2
|
| Sequence（Three letter abbreviations）
|
Ac-{TYR}{THR}{SER}{LEU}{ILE}{HIS}{SER}{LEU}{ILE}{GLU}{GLU}{SER}{GLN}{ASN}{GLN}{GLN}{GLU}{LYS}{ASN}{GLU}{GLN}{GLU}{LEU}{LEU}{GLU}{LEU}{ASP}{LYS}{TRP}{ALA}{SER}{LEU}{TRP}{ASN}{TRP}{PHE}-NH2
|
| C-port
|
NH2
|
| Basic description
|
36 residue synthetic peptide that inhibits HIV-1 fusion with CD4 cells. N-terminal acetylated, C-terminal amide. Enfuvirtide is the first in this class to reach market approval. Fusion inhibitors block the last step in the three-step viral entry process consisting of attachment, co-receptor binding and fusion, thereby preventing viral capsid entry into the host cell. Enfuvirtide has a unique mechanism of action and viral target specificity, and in clinical trials has been shown to exhibit both efficacy and low toxicity. Enfuvirtide is a peptide mimetic of an essential region within viral envelope glycoprotein gp41 that functions by blocking gp41 structural rearrangements at a transitional pre-fusion conformation.
|
| The molecular weight
|
4491.880
|
| Chemical formula
|
C204H301N51O64
|
| The purity
|
> 95%
|
| N-port
|
Ac
|
| Storage conditions
|
Store at -20°C. Keep tightly closed. Store in a cool dry place.
|
| Annotation
|
HIV-I TAT Protein Peptide
|
| Documents
|
|
| Figures
|
|
| Reference
|
Mink M, Mosier SM et al. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J Virol. Oct 2005;79(19):12447-54.
|
Enfuvirtide (T-20)
